NCT02002598 : Phase 1 /2 -Carfilzomib + Bendamustine and Dex in New MM

This study is designed to define dose-limiting toxicity and determine preliminary evidence of efficacy of Carfilzomib (CFZ) in combination with bendamustine and dexamethasone for patients with newly diagnosed multiple myeloma (MM).

Columbia University

ClinicalTrials.gov Identifier: NCT02002598

Official Title: Phase I/II Study of Carfilzomib in Combination With Bendamustine and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

---

Carfilzomib : National Cancer Institute

Carfilzomib : MedlinePlus Drug Information

Bendamustine: National Cancer Institute

Bendamustine: MedlinePlus Drug Information

Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information

---

Blood Cancer J : Feb 3, 2020

PMID: 32015343

Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma